An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2017
At a glance
- Drugs XmAb 5871 (Primary)
- Indications Immunological disorders
- Focus Therapeutic Use
- Sponsors Xencor
- 04 Nov 2017 According to a Xencor media release, primary endpoint has been met. (Proportion of patients with an improvement in IgG4-RD activity).
- 04 Nov 2017 Results presented in a Xencor Media Release.
- 04 Nov 2017 According to a Xencor media release, data were presented at the American College of Rheumatology (ACR) 2017 Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History